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microRNA miR-221 is frequently over-expressed in a variety of human neoplasms. Aim of
this study was to identify new miR-221 gene targets to improve our understanding on the
molecular tumor-promoting mechanisms affected by miR-221. Gene expression profiling
of miR-221-transfected-SNU-398 cells was analyzed by the Sylamer algorithm to verify
the enrichment of miR-221 targets among down-modulated genes. This analysis revealed
that enforced expression of miR-221 in SNU-398 cells caused the down-regulation of 602
mRNAs carrying sequences homologous to miR-221 seed sequence within their 3′UTRs.
Pathways analysis performed on these genes revealed their prominent involvement in cell
proliferation and apoptosis. Activation of E2F, MYC, NFkB, and β-catenin pathways was
experimentally proven. Some of the new miR-221 target genes, including RB1, WEE1 (cell
cycle inhibitors), APAF1 (pro-apoptotic), ANXA1, CTCF (transcriptional repressor), were
individually validated as miR-221 targets in SNU-398, HepG2, and HEK293 cell lines. By
identifying a large set of miR-221 gene targets, this study improves our knowledge about
miR-221 molecular mechanisms involved in tumorigenesis. The modulation of mRNA level
of 602 genes confirms the ability of miR-221 to promote cancer by affecting multiple
oncogenic pathways.
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INTRODUCTION
miR-221 is among the most frequently up-regulated miRNAs in
human cancer. It is over-expressed in a large fraction of glioblas-
toma, liver, bladder, thyroid, pancreatic, gastric, and prostate
carcinomas (Gottardo et al., 2007; Lee et al., 2007; Visone et al.,
2007; Fornari et al., 2008; Mercatelli et al., 2008; Pineau et al.,
2010; Liu et al., 2012; Quintavalle et al., 2012). In few cases,
non-oncogenic functions of miR-221 were reported. For exam-
ple, the regulation of c-kit by both miR-221 andmiR-222 induced
anti-angiogenic effects and the reduction of cell proliferation of
herythroleukemic cells (Felli et al., 2005), suggesting that miR-221
effects could also depend on cellular context. Its suggested role
in tumorigenesis was confirmed by the finding that miR-221
over-expression correlates with tumor aggressive features, such
as the presence of metastasis and multifocal lesions in hepato-
cellular carcinoma (HCC) (Gramantieri et al., 2009; Fu et al.,
2011). In vitro studies showed that miR-221 caused an increase
in cell proliferation rate and invasion capability, while anti-miR-
221 induced a decrease in cell growth and promoted apoptosis
(Fornari et al., 2008; Garofalo et al., 2009; Pineau et al., 2010;
Zhang et al., 2010b). In vivo studies proved that miR-221 could
induce proliferation of tumorigenic murine hepatic progenitors
cells (Pineau et al., 2010) and accelerate liver tumor formation
in a miR-221 over-expressing transgenic mouse model (Callegari
et al., 2012).
These observations underline the importance of miR-221 in
tumorigenesis, in particular for HCC, and the value of under-
standing the molecular mechanisms controlled by miR-221. To
this purpose, identification of gene targets could provide the
links between miR-221 over-expression and pathways involved in
human cancer. Some important gene targets have been already
identified: the cyclin-dependent kinase inhibitors CDKN1B/p27
and CDKN1C/p57 (Galardi et al., 2007; le Sage et al., 2007;
Fornari et al., 2008; Medina et al., 2008), the pro-apoptotic fac-
tors BMF (Gramantieri et al., 2009) and BBC3/PUMA (Zhang
et al., 2010a,b), PTEN (Garofalo et al., 2009), an inhibitor
of PI3K/AKT pathway, PTPμ (Quintavalle et al., 2012), a
tyrosin-phosphatase that participates in cell adhesion regula-
tion, and TIMP3 (Garofalo et al., 2009), a metallopeptidase
inhibitor.
These miR-221 targets revealed tumor-promoting mecha-
nisms associated with miR-221 over-expression. However, our
knowledge about miR-221 molecular targets is largely incom-
plete and aim of this work was to reveal the many additional
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miR-221 targets with a high-throughput approach to identify
most of its gene targets and improve our understanding of the
multiple mechanisms that are affected by miR-221.
MATERIALS AND METHODS
SYLAMER ANALYSIS AND BIOINFORMATICS
Gene expression analysis of miR-221 transfected SNU-398 cells
and Negative Control 2 (NC2, AM17111, Ambion) treated
SNU-398 samples were performed using Agilent Whole Human
Genome Oligo Microarray platform (Agilent Technologies),
following manufacturer’s procedures, as previously described
(Ferracin et al., 2008). GeneSpring GX 11 software (Agilent
Technologies) was used to analyze results. Data transformation
was applied to set all the negative raw values to 1.0, followed
by a quantile normalization. A filter on low gene expression
was used to keep only the probes classified as Detected in at
least one sample by the software. Array results were submit-
ted in ArrayExpress (http://www.ebi.ac.uk/arrayexpress/, acces-
sion number E-MTAB-1531). Genes were ordered according to
fold-change, from the most down-regulated to the most up-
regulated in miR-221 transfected cells and the ordered gene list
was analyzed with the Sylamer algorithm (EMBL-EBI), through
the web-interface SylArray (http://www.ebi.ac.uk/enright-srv/
sylarray) (Bartonicek and Enright, 2010). The Sylarray system
assigned 3′UTR sequences to each mappable probe and fil-
tered for low-complexity sequences, redundancy and multiple
probe mappings. The Sylamer algorithm was applied to search
for enrichment or depletion of miRNA seed sequences in the
3′UTRs ranked according to the gene list provided. The soft-
ware generated plots representing the hypergeometric statistic
significance of each nucleotide words across whole gene list.
According to Sylamer method, the peak of the 7-mer plot clos-
est to the start of the ranking was chosen as a conservative
threshold to select putative miR-221 target genes (van Dongen
et al., 2008). Algorithms used to identify predicted miR-221 target
genes were TargetScan v. 5.2 (http://www.targetscan.org) (Lewis
et al., 2005), MicroCosm v. 5 (http://www.ebi.ac.uk/enright-srv/
microcosm/htdocs/targets/v5), Diana MicroT v.3 (http://diana.
cslab.ece.ntua.gr/microT/) (Maragkakis et al., 2009). For path-
way analysis we used GeneSpring GX v.11 and GeneGo (Nikolsky
et al., 2005) software through the functions for finding significant
pathways.
PLASMID VECTORS
pMIF-GFP-miR-221 was prepared by cloning hsa-miR-221 gene
in the pMIF-GFP-Zeo plasmid (System Biosciences), using the
NheI restriction site. psiCheck-3′UTR constructs were prepared
by cloning portions of 3′UTR (that contained miR-221 seed
complementary regions) of putative target genes into psiCheck-
2 vector (Promega), downstream of the renilla luciferase gene,
using XhoI and PmeI restriction sites. The primers used to
amplify 3′UTR regions and the lengths of cloned regions are
listed in Table S1. psiCheck-RB1-3′UTR-mutated was obtained
by deleting two 6-nucleotides regions, corresponding to miR-221
complementary regions, in RB1-3′UTR sequence of psiCheck-
RB1-3′UTR.Mutagenesis was performed by Genescript company.
All constructs were verified by sequencing.
CELL CULTURES, TRANSFECTIONS, AND LUCIFERASE ACTIVITY
ASSAYS
SNU-398, HepG2, and Hek293, from American Type Culture
Collection, were cultured in Iscove Modified Dulbecco’s Medium
(IMDM) supplemented with 10% fetal calf serum (Sigma-
Aldrich) and 0.1% Gentamicin (Sigma-Aldrich).
For miRNA precursor transfection, cells were seeded
in 24-well plates at a density of 100,000 cells/well, 24 h
before transfection. Transfection was performed according
to Lipofectamine2000 protocol (Invitrogen), using Optimem
medium (Invitrogen-Gibco). miR-221 precursor (AM17100—
PM10337) and negative control #2 (NC2—AM17111) were
obtained from Ambion and were transfected at the final con-
centration of 100 nM. The anti-miR-221 oligonucleotide was
synthetized by Integrated DNA Technology (IDT) and it has
the following sequence: 5′-mG∗mA∗mA mAmCmC mCmAmG
mCmAmG mAmCmA mAmUmG mU∗mA∗mG∗ mC∗mU-3′
(m, methylated nucleotide; ∗, phosphothioate bond). It was
transfected at the final concentration of 100 nM.
Luciferase vectors (psiCheck-based vectors) were transfected
at the final concentration of 800 ng/ml. Each transfection was
performed in triplicate. For RNA extraction, cells were col-
lected 48 h after transfection and the RNA was extracted fol-
lowing Trizol protocol (Invitrogen). For luciferase assays, firefly
and renilla luciferase activity were measured using the Dual-
Luciferase Reporter Assay (Promega), 24 h after transfection. The
firefly luciferase activity was used to normalize the reporter renilla
luciferase signal.
To experimentally investigate the involvement of miR-221 in
cancer processes, we used the Cignal Finder 10-Pathway Reporter
Arrays kit (SABiosciences), a commercial reporter array that
allows for simultaneous evaluation of 10 cancer-related signaling
pathways activation. It is a reverse transfection system that makes
use of specific pathway-focused transcription factor-responsive
firefly luciferase vectors. Ten thousand cells were seeded in
wells containing the responsive and normalization vectors and
luciferase activities were measured after 48 h. Data normaliza-
tion was based on an included vector that expresses the renilla
luciferase gene under the control of the strong cytomegalovirus
(CMV) promoter.
miR-221 STABLE CELL CLONES
SNU-398 cells were transfected with pMIF-GFP-miR-221 plas-
mid. After 24 h from transfection cells were diluted and cul-
tured in IMDM Medium supplemented with 10% fetal calf
serum (Sigma-Aldrich), 0.1% Gentamycin (Sigma-Aldrich) and
400μg/ml of zeocin. After 4 weeks, single colonies were picked
up and miR-221 expression was evaluated using Real Time PCR.
REAL TIME PCR
The RNA purification by Trizol was performed according to
manufacturer’s indications (Invitrogen). For mature microRNA
quantification we performed a Taqman Real time PCR, using
miR-221 probe (Applied Biosystems). Five nanogram of puri-
fied RNA were retro-transcribed using TaqMan MicroRNA
Reverse Transcription kit (Applied Biosystems) and mature miR-
221 MicroRNA Assay (Applied Biosystems, assays ID000524),
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following manufacturer’s protocol. Real Time quantitative PCR
was performed using TaqMan MicroRNA Assay specific for hsa-
miR-221 (Applied Biosystems, assays ID000524) and for hsa-miR-
222 (Applied Biosystems, assays ID002276). The reaction was
carried out in a 96-well PCR plate at 95◦C for 10min followed
by 40 cycles of 95◦C for 15 s and 60◦C for 1min on Biorad-
Chromo4 thermal cycler real-time PCR instrument. Each sample
was analyzed in triplicate. The level of miRNA was measured
using Ct (threshold cycle) and the amount of target was calculated
using 2−Ct method. To normalize the expression levels of miR-
221, TaqMan endogenous control RNU6B (Applied Biosystem,
assay ID001093) was used. For gene expression analysis we per-
formed Real Time EvaGreen PCR. Five hundred nanogram of
total RNA were retro-transcribed using random examers and
oligo dT. Diluted cDNAs (1:5 for ANXA1, 1:10,000 for 18S and
1:100 for RB1, APAF1, WEE1, CTCF, GAPDH) were amplified in
Real Time PCR using Qiagen Taq DNA Polymerase (QIAGEN,
201203) for EvaGreen (Biotium Inc.; 0.2× final concentra-
tion) detection. The following primers were used: RB1_2612F
(TCA GAA GGT CTG CCA ACA CCA ACA), RB1_2744R
(TGA GCA CAC GGT CGC TGT TAC ATA); APAF1_1046F
(GGC TGT GGG AAG TCT GTA TTA G), APAF1_1195R (CAA
CCG TGT GCA AAG ATT CTG); ANXA1_835F (TGG AGT
TGA AAG GTG ACA TTG), ANXA1_982R (CGG GAA ACC
ATA ATC CTG ATC); WEE1_1994F (CGA ATA GAA TTG
AAT GCC GAA AAG), WEE1_2142R (GAT GTT CTA TTA
CTC TGG GTG G); CTCF_1499F (AGT GTT CCA TGT GCG
ATT AC), CTCF_1654R (GGG TTC TCA TGT GCC TTT
TC); GAPDH_1107F (CTA TAA ATT GAG CCC GCA GCC),
GAPDH_1257R (CCC AAT ACG ACC AAA TCC GT); 18S_616F
(AGC AGC CGC GGT AAT TCC AGC T), 18S_784R (CGG GAC
ACT CAG CTA AGA GCA TC). The reactions were incubated
in a 96-well PCR plate at 95◦C for 15min followed by 40 cycles
of 95◦C for 30 s and 58◦C for 30 s. Each sample was analyzed
in triplicate. Fluorescence measurements were completed using a
Biorad-Chromo4 thermal cycler real-time PCR instrument. The
level of each mRNA was measured using Ct (threshold cycle) and
the amount of target was calculated using 2−Ct method. Gene
expression levels were normalized using either 18S or GAPDH
expression.
WESTERN BLOTTING AND ANTIBODIES
Cells were collected by trypsin-EDTA and dissolved in RIPA
buffer (Radio-Immunoprecipitation Assay) (Sigma-Aldrich),
supplemented with Protease inhibitors (Sigma-Aldrich), accord-
ing to Manufacturer’s protocol. The following antibodies
were used: anti-human Retinoblastoma Protein (554136—BD
Biosciences, 1:250), anti-APAF1 (clone E38, Millipore, 1:1000),
anti-ANXA1 (sc-11387, Santa Cruz Biotechnology, 1:500), anti-
WEE1, (sc-325, Santa Cruz Biotechnology, 1:500), monoclonal
anti-actin (A4700, Sigma-Aldrich, 1:1000), HRP-linked anti-
mouse antibody (A9044, Sigma-Aldrich, 1:20,000), HRP-linked
anti-rabbit antibody (7074, Cell Signaling, 1:40,000). For sig-
nal detection LiteAblot Turbo Extra-Sensitive Chemiluminescent
Substrate (Euroclone) was used. Signals were quantified by the
ImageJ software (http://rsbweb.nih.gov/ij/) and protein expres-
sion levels were normalized according to β-actin expression.
STATISTICAL ANALYSIS
The significance of differential expression in luciferase assays and
quantitative PCRs between groups was assessed by student’s t-test.
RESULTS
miR-221 CAN DOWN-MODULATE HUNDREDS OF GENE TARGETS BY
REDUCING THEIR RNA LEVELS
To identify genes controlled by miR-221, we compared gene
expression profiling of SNU-398 cells transfected with miR-221
precursor vs. SNU-398 cells transfected with negative control
(NC2, Ambion). This cell line was chosen because it expresses
low level of miR-221 (Fornari et al., 2008). In our experimen-
tal setting, miR-221 transient transfection induced a ≈10-fold
increase in microRNA expression. No expression changes were
detected for the related miR-222 (Figure S1). Three independent
experiments ofmiR-221 transfections vs. four independent exper-
iments of NC2 transfections were compared. Following quantile
normalization and exclusion of undetectable or compromised
probes, 26,586 DETECTED probes, according to Agilent Feature
Extraction analysis software, were used.
Comparison of the average expression level of these probes
between miR-221 vs. NC experimental groups was performed
and each probe was then ordered according to fold change, from
the most down-regulated to the most up-regulated of the miR-
221-transfected cells group. The Sylamer algorithm, through the
web-based interface Sylarray, was used to analyze the ordered
gene list of mRNAs. First, the algorithm filters out genes with
low complexity 3′UTRs and selects one probe for each of the
maintained genes. Following this selection, Sylamer analysis was
applied to a reduced list comprising 11,971 genes (Table S2).
A highly significant (p-value = 1 × 10−15) enrichment for miR-
221 target sequences was detected in the 3′UTRs of many of the
down-regulated genes (Figure 1).
According to Sylamer indications, the cut-off was chosen in
correspondence to the peak closest to the start of the rank-
ing in the 7-mer plot, which led to the selection of the first
1800 most down-regulated mRNAs in miR-221 transfected cells
(reduced FC<−1.15), (Figure 1). Within this cut-off, the algo-
rithm detected the presence of at least one seed complementary
region for miR-221 in 602 genes (33.4%) (Table S3). All included
the hexamer TGTAGC (corresponding to the nts 2–7 of miR-221
seed); 238 included the heptamer TGTAGCA (corresponding to
the nts 2–8 of seed); 310 included the heptamer ATGTAGC (cor-
responding to the nts 1–7 of seed); 120 included the octamer
ATGTAGCA (corresponding to the nts 1–8 of the seed).
To assess the value of these results, we verified the presence of
validated targets within these lists. In a list of 35 published targets
of miR-221 (http://www.genego.com/, August 2012), 10 (ARHI,
ESR1, SLM1, KIT, PIK3KR1, SEMA6D, SLC4A4, TNF, FOG2,
ICAM) could not be evaluated because their expression was unde-
tectable in SNU-398 cells. Among the remaining 25 genes, 14
(PUMA, BMF, CDKN1B, CDKN1C, GARNL1, MDM2, THRB,
APAF1, TIMP3, TRPS1, ZADH2, RP42, DVL2, and Connexin43)
were identified by Sylamer within the list of the 1800 most down-
regulated genes; five (SEC62, FOXO3, Hox-B6, SIP2, and PTPR-
mu), although still down-regulated, were outside the selected
cut-off and six were found slightly up-regulated (Dicer, BIM,
www.frontiersin.org April 2013 | Volume 4 | Article 64 | 3
Lupini et al. miR-221 gene targets
FIGURE 1 | Sylamer enrichment landscape plots. Plots show the 6nt, 7nt,
and 8nt seed complementary enrichment profiles. The graph shows that the
words complementary to the seed region of miR-221 (in red and orange)
clearly separate from the background, which consists of the seeds of all the
other miRNAs. For each plot the x-axis represents the sorted gene list from
the most down-regulated (left) to the most up-regulated (right) mRNAs in
miR-221 transfected cells and the y-axis shows the hypergeometric
significance of each nucleotide word. The multiple testing bounds for
adjusted P < 0.05 is: ±4.286 for 6-mers, ±4.199 for 7-mers, and ±3.923 for
8-mers.
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NLK, PTEN, REDD1, and Ets1) (Table S4). We cannot exclude
the possibility that down-regulation of these latter genes could
be detectable at protein but not mRNA level. In any case, these
results indicate that a significant portion (56%) of the published
validated gene targets could have been identified through this
approach and suggest that many of the additional targets yet to
be validated are likely present within this list.
The published gene targets detected by Sylamer contained
at least 1 or 2 complementary sites for the 7-mer seed within
their 3′UTRs. As expected, with the exception of RALGAPA1
(or GARNL1), THRB and Connexin43, the remaining 10 proven
gene targets were predicted by at least one of the online pro-
grams MicroCosm, Targetscan or Diana microT, indicating that
presently known gene targets were largely identified through an
initial scanning using available online predictions.
We intersected the 602 genes that emerged from Sylamer anal-
ysis with genes predicted by three online algorithms (MicroCosm,
Targetscan, Diana microT). Overall, 125 genes identified by
Sylamer (19.9%) were also predicted by online algorithms
(Table S5). This set of 125 genes are therefore not only predicted
by online algorithms, but also emerged in an experimental setting
based on microarray expression analyses, thus adding a new level
of confidence to these genes as miR-221 real targets.
miR-221 INDUCED PRO-PROLIFERATIVE PATHWAYS INVOLVED
IN CANCER
We investigated the biological processes associated with the genes
that emerged from Sylamer analysis: the 602 genes with at least
one site matching the seed sequence of miR-221 were analysed
for detecting their association with molecular pathways through
the use of Genespring GX 11 (Agilent Technologies) and GeneGO
(Thomson Reuters) programs.
Both methods provide a rapid categorization of large lists of
genes into functionally related groups of genes. At the p-value cut-
off of 0.05, Genespring and GeneGO found several pathways that
were enriched in genes targeted by miR-221 (Tables 1, S6). Many
of these genes were related to cell cycle regulation and apoptosis.
To directly investigate the involvement of miR-221 in cancer
processes, we used Cignal Finder 10-Pathway Reporter Arrays
kit (SABiosciences), a commercial reporter array that allows for
Table 1 | Pathways affected by miR-221, based on Genespring and
GeneGo analysis of target genes.
Pathway Average p-valuesa
GeneGo Genespring
Cell adhesion: ECM remodeling,
Cadherin-mediated, Ephrin signaling
8,55E-05 2,93E-03
TGF, WNT, and cytoskeletal remodeling 1,71E-05 2,89E-02
P53 signaling pathway 1,33E-04 2,20E-02
Cell cycle regulation 9,94E-05 2,16E-02
Growth factors signaling 7,10E-05 2,35E-02
Signaling in macrophages, B and T
lymphocytes
1,78E-04 2,82E-02
aBased on data of Table S6.
simultaneous evaluation of 10 cancer-related signaling pathways
activation levels in cells, using specific pathway-focused transcrip-
tion factor-responsive firefly luciferase constructs. This kit was
used to evaluate the ability of miR-221 to induce cancer-related
pathways in the SNU-398/miR221 clone 2 cells, engineered to sta-
bly express increased levels of miR-221 (Figure S1). We found
that four pathways, Myc/Max, NFkB, Wnt/β-catenin, and RB-
E2F, were significantly induced in miR-221 expressing cells, com-
pared to the original cells (p-value <0.05) (Figure 2), thereby
confirming miR-221 involvement in cellular processes that can
induce proliferation and suppress apoptosis.
VALIDATION OF NOVEL CANCER-ASSOCIATED TARGETS OF miR-221
From the list of genes identified by Sylamer and the list of path-
ways significantly affected by miR-221, we focused our attention
on genes involved in cell proliferation and apoptosis regulation
to individually validate them as miR-221 targets. They included
the cell cycle regulators retinoblastoma 1 (RB1) and WEE1,
the pro-apoptotic gene Apoptotic Peptidase Activating Factor
1 (APAF1), CCCTC-binding factor (CTCF), a transcriptional
repressor and Annexin A1 (ANXA1). In addition, we also inves-
tigated Fas Ligand (FASLG), which contains a miR-221 target
region in its 3′UTR, but was not within the Sylamer-derived-
602 genes list. The genes studied are listed in Table 2 and in
Figure S2.
To validate potential miR-221 target genes, we first performed
luciferase assays. We cloned a portion of the 3′UTRs contain-
ing miR-221 target sequences into a psiCheck-2 reporter vec-
tor, downstream the luciferase reporter gene. We assayed the
luciferase activity in the presence or absence of added miR-
221 mimics in three different cell lines: HEK-293 (embryonic
kidney derived cells) and two hepatocarcinoma derived cells
(SNU-398, HepG2). The reporter vector constructs were trans-
fected into cells together with miR-221 precursor or negative
control (NC2). We found that miR-221 induced a signifi-
cant decrease in luciferase activity of all the vectors contain-
ing 3′UTRs of genes identified through the Sylamer approach.
Instead, no change in luciferase activity could be detected for
the psiCheck-FASLG 3′UTR vector (Figure 3A). In the case of
RB1, to confirm that the decrease in luciferase activity was specif-
ically linked to the miR-221 complementary regions present
in the 3′UTR, we prepared a mutant form of psiCheck-RB1
3′UTR (psiCheck-RB1 3′UTR mutated) that lacks the miR-
221 target sequences within the RB1 3′UTR. Mutation of these
sites made the vector unresponsive to miR-221 inhibitory effect
(Figure S3).
The ability of miR-221 to induce a decrease in RB1, APAF1,
ANXA1, WEE1, and CTCF expression was further demonstrated
by measuring the relative amount of their mRNAs in SNU-
398 and HepG2 cell lines. We found a significant decrease (p-
value <0.003) of RB1 mRNAs in both cell lines transfected
with miR-221 (−64% in SNU-398 and −72% in HepG2); sim-
ilarly, we found 26 and 42% decrease in APAF1 mRNA level,
respectively, in SNU-398 and HepG2 (p-value <0.015); miR-
221 caused a decrease of 38% (SNU-398) and 77% (HepG2) of
ANXA1 mRNA (p-value <0.018); WEE1 mRNA was 44% (SNU-
398) and 61% (HepG2) less expressed in presence of microRNA
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FIGURE 2 | Cellular pathways induced by miR-221. The Cignal Finder
10-Pathway Reporter Arrays (SABiosciences) was employed. Relative
luciferase activity was measured in SNU-398 (low miR-221 expression)
or in SNU-398/miR221 clone 2, which shows a miR-221 expression
about 2.5-fold higher than in SNU-398 cells (see Figure S1). Each
condition was measured in triplicate. A t-test was used to compare
the average expression of each condition in the two cell lines. Wnt,
cell cycle, NFkB, and Myc exhibited a significant increased activity
in the SNU-398/miR221 cells. ∗p-value ≤ 0.05; ∗∗p-value ≤ 0.01;
∗∗∗p-value ≤ 0.001.
Table 2 | Genes individually validated as miR-221 targets.
Gene Gene Sylamer 3′UTR length Number of miR-221 Fold-changeb Online
symbol positiona (bp) target sequences predictionc
Retinoblastoma 1 RB1 1087 1915 2 −1, 2
Apoptotic Peptidase Activating Factor 1 APAF1 430 2945 2 −1, 3
Annexin A1 ANXA1 1580 718 2 −1, 16 M
WEE1 homolog (S. Pombe) WEE1 1598 1382 1 −1, 16
CCCTC-binding factor (zinc finger protein) CTCF 302 1308 2 −1, 37 D
Fas ligand (TNF superfamily, member 6) FASLG N/A 907 1 N/A
aPosition within the first 1800 most down-regulated mRNAs.
bCalculated on the basis of microarray experiments (3 miR-221 vs. 4 NC2).
cM, Microcosm; D, Diana microT; T, Targetscan.
(p-value <0.013) and CTCF mRNA showed a 38% decrease
in miR-221 transfected SNU-398 cells (p-value = 0.006), while
in HepG2 we found a slight (but not significant) decrease
(Figure 3B), meaning that specific cell background could mod-
ulate microRNA effects on target genes.
Finally, protein expression analyses revealed that miR-221
could indeed decrease the levels of RB1, WEE1, APAF1, and
ANXA1 proteins in SNU-398 cells; conversely, an oligonucleotide
anti-miR-221 induced their increase in SNU-398/miR-221 sta-
ble clone (Figure 3C). We could not test CTCF protein, because
available antibodies produced poor quality results.
DISCUSSION
We have added a number of novel gene targets to those already
identified for miR-221. In this study, we did not use the tradi-
tional “in silico” prediction, followed by the individual validation
of the most interesting ones. In fact, through this approach,
various important miR-221 gene targets have been already iden-
tified (Galardi et al., 2007; le Sage et al., 2007; Fornari et al.,
2008; Medina et al., 2008; Garofalo et al., 2009; Gramantieri
et al., 2009; Zhang et al., 2010a,b; Quintavalle et al., 2012) (see
also Table S4). Here, we used an approach that was based on
Sylamer analysis of gene expression profiling. Sylamer couples
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FIGURE 3 | Validation of few individual miR-221 target genes.
(A) Luciferase assays were performed in Hek293, SNU-398, and HepG2 cells
transfected with miR-221 or negative control (NC2), together with psiCheck
luciferase vectors containing portions of the 3′UTR of the investigated genes
placed downstream the renilla luciferase gene. The renilla luciferase activity
was normalized on firefly luciferase activity. Compared to NC2 controls,
miR-221 induced a significant decrease in luciferase activity of the vectors
containing the RB1, APAF1, ANXA1, WEE1, and CTCF 3 UTR. In contrast,′
3′UTR-luciferase vector and the psiCheck control vector. ∗∗p-value ≤ 0.01;
∗∗∗p-value ≤ 0.001. (B) RB1, APAF1, ANXA1, WEE1, and CTCF mRNA
expression was measured in SNU-398 and HepG2 cells following transfection
with miR-221 or NC2 using Real Time PCR. A significant reduction in mRNA
levels was detected for all the investigated genes, with the exception of
CTCF mRNA in HepG2 cells. ∗p-value ≤ 0.05; ∗∗p-value ≤ 0.01;
∗∗∗p-value ≤ 0.001. (C) Protein expression levels were assessed by Western
blot analysis. miR-221 induced a decrease in RB1, APAF1, ANXA1, and WEE1
proteins in SNU398 cells, while transfection of anti-miR-221 into
SNU-398/miR-221 stable clone induced an increase in target protein levels.
Numbers indicate the fold change decrease or increase of proteins
expression in miR-221 or anti-miR-221 transfected cells vs. the respective
controls. Protein expression levels were normalized vs. β-actin expression.
experimental gene expression results to the search for microRNA
target sequences in the 3′UTR of genes. By using this approach,
we could identify 602 miR-221 gene targets, among which 125
were also predicted by at least one prediction algorithm. For
this latter group of genes, our experimental results add a new
level of confidence to their inclusion among the true targets of
miR-221.
The enforced expression of miR-221 did not alter the level of
miR-222. Hence, the targets reported by this study may actually
be specifically regulated just by miR-221. However, by sharing the
www.frontiersin.org April 2013 | Volume 4 | Article 64 | 7
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same seed sequence, it is possible that many of the discovered
genes could potentially be targets of miR-222 too. More specific
experiments would be required to formally prove this point.
To achieve these results, in this study we did not employ the
traditional t-test analysis, which is used to select the genes with
a significant differential expression level between two groups of
samples. In fact, this approach would have been too stringent and
many real targets excluded. For example, two known targets, such
as CDKN1B (Gramantieri et al., 2008) and BMF (Gramantieri
et al., 2009) were among the down-modulated genes, but their
p-value was not significant (Table S2). Analysis based on Sylamer
did not produce this bias. Even slight, apparently non-significant
effects on mRNA modulation could be picked up by Sylamer if
the gene is present in the context of a group of genes that share the
characteristic of having homology with the same miRNA’s seed. It
should also be considered that this assay takes into account only
miRNA effects on the stability of target mRNAs, without consid-
ering its effect on mRNA translation, which is often predominant
in mammalian cells.
To validate some of the results, we also applied the tradi-
tional approach to few of them, RB1, APAF1, WEE1, CTCF, and
ANXA1: the assessment of mRNA and protein levels following
miRNA or anti-miRNA enforced expression and luciferase assays
were used to prove direct interaction with predicted target sites.
In addition, for RB1, mutation of the putative miR-221 target
site was shown to abolish the miR-221 regulation. Notably, we
also identified Anxa1 as strongly down-regulated in a proteomic
screening performed in SNU-398 cells transfected with miR-221
(Corrales, data not shown), further confirming Anxa1 as tar-
get of miR-221 regulation. APAF1 was recently independently
demonstrated as miR-221 target in lung cancer derived-cell lines
(Quintavalle et al., 2012), thereby giving support to our finding.
Conversely, FAS ligand, a gene that contains a miR-221 targeting
site within its 3′UTR, but was not present among the down-
regulated mRNAs detected in this study, was not validated as a
miR-221 target by luciferase assay. In general, all the individually
tested genes confirmed to be targets of miR-221, suggesting that
most, if not all the 602 genes identified through expression pro-
filing and Sylamer analysis may represent truly novel gene targets
modulated by miR-221. Taken together, these findings show that
this approach represents a feasible and effective method for the
identification of large sets of valid miRNA targets.
Pathway analysis of the 602 putative miR-221 target genes
revealed that these genes are involved in cellular processes related
to cell cycle regulation and apoptosis. Experimental tests revealed
that various pathways, which included WNT/β-catenin, E2F/RB
cell cycle, MYC and NFkB, may be promoted by miR-221 over-
expression.
Previous experiments demonstrated that miR-221 was able
to induce tumor cells proliferation, both in vitro (Galardi et al.,
2007; le Sage et al., 2007; Fornari et al., 2008; Gramantieri et al.,
2009) and in vivo models (Pineau et al., 2010; Callegari et al.,
2012). Among these pathways, inhibition of RB1 protein may
explain the activation of the E2F pathway and support the impor-
tant role of miR-221 in cell cycle progression. Indeed, it was
previously shown that miR-221 can repress the CDK inhibitors
CDKN1B and CDKN1C (both confirmed in this study), and RB1
represents the third negative regulator of cell cycle that appear
to be controlled by miR-221. This finding supports the observa-
tion that miR-221 could induce a significant increase of Hep3B
HCC cells in S-phase and a decrease of cells in G1-phase (Fornari
et al., 2008). This finding suggests that impairing cell cycle control
mechanisms is one of themain effects of miR-221 over-expression
in human cancer. The present work has led to the discovery of
hundreds of new miR-221 target genes and provides an exam-
ple of the multiple molecular functions that a single deregulated
miRNA could affect. This is relevant for the establishment of
miRNA-based therapeutics: multiple pathways could be simul-
taneously affected when miRNA or anti-miRNA are given as
therapeutic molecules. The tumor promoting activity of miR-221
has been recently confirmed and supported by in vivo models
also by showing the anti-tumor effect achieved by anti-miR-221
oligonucleotides: anti-miR-221 could significantly inhibit tumor
cell proliferation of human HCC xenografts (Park et al., 2011)
as well as reduce the number and size of liver tumors in a trans-
genic mouse model (Callegari et al., 2012). The present results
add new information about the molecular pathways controlled by
miR-221, thus contributing to explain how this microRNA could
promote tumorigenesis and how to better assess the effect of its
inhibition.
This work, by showing that the Sylamer algorithm could reveal
the enrichment for a miRNA seed sequence among a group of
down-regulated mRNAs, represents a general approach that could
be applied to any miRNA for the experimental identification of
a wide range of gene targets. In the case of miR-221, the list
of modulated mRNAs was used to improve our understanding
of its role in tumor pathways. However, these results may poten-
tially be useful for defining the molecular mechanisms that are
influenced in any other physiological or pathological condition in
which miR-221 could be eventually implicated.
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